Literature DB >> 20179087

Identification of eight novel coagulation factor XIII subunit A mutations: implied consequences for structure and function.

Vytautas Ivaskevicius1, Arijit Biswas, Carville Bevans, Verena Schroeder, Hans Peter Kohler, Hannelore Rott, Susan Halimeh, Petro E Petrides, Harald Lenk, Manuele Krause, Bruno Miterski, Ursula Harbrecht, Johannes Oldenburg.   

Abstract

BACKGROUND: Severe hereditary coagulation factor XIII deficiency is a rare homozygous bleeding disorder affecting one person in every two million individuals. In contrast, heterozygous factor XIII deficiency is more common, but usually not associated with severe hemorrhage such as intracranial bleeding or hemarthrosis. In most cases, the disease is caused by F13A gene mutations. Causative mutations associated with the F13B gene are rarer. DESIGN AND METHODS: We analyzed ten index patients and three relatives for factor XIII activity using a photometric assay and sequenced their F13A and F13B genes. Additionally, structural analysis of the wild-type protein structure from a previously reported X-ray crystallographic model identified potential structural and functional effects of the missense mutations.
RESULTS: All individuals except one were heterozygous for factor XIIIA mutations (average factor XIII activity 51%), while the remaining homozygous individual was found to have severe factor XIII deficiency (<5% of normal factor XIII activity). Eight of the 12 heterozygous patients exhibited a bleeding tendency upon provocation.
CONCLUSIONS: The identified missense (Pro289Arg, Arg611His, Asp668Gly) and nonsense (Gly390X, Trp664X) mutations are causative for factor XIII deficiency. A Gly592Ser variant identified in three unrelated index patients, as well as in 200 healthy controls (minor allele frequency 0.005), and two further Tyr167Cys and Arg540Gln variants, represent possible candidates for rare F13A gene polymorphisms since they apparently do not have a significant influence on the structure of the factor XIIIA protein. Future in vitro expression studies of the factor XIII mutations are required to confirm their pathological mechanisms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20179087      PMCID: PMC2878794          DOI: 10.3324/haematol.2009.017210

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  15 in total

1.  Mutations affecting disulphide bonds contribute to a fairly common prevalence of F13B gene defects: results of a genetic study in 14 families with factor XIII B deficiency.

Authors:  V Ivaskevicius; A Biswas; R Loreth; V Schroeder; S Ohlenforst; H Rott; M Krause; H-P Kohler; I Scharrer; J Oldenburg
Journal:  Haemophilia       Date:  2010-03-10       Impact factor: 4.287

2.  A photometric assay for blood coagulation factor XIII.

Authors:  K Fickenscher; A Aab; W Stüber
Journal:  Thromb Haemost       Date:  1991-05-06       Impact factor: 5.249

3.  Three-dimensional hydrogen-bond geometry and probability information from a crystal survey.

Authors:  J E Mills; P M Dean
Journal:  J Comput Aided Mol Des       Date:  1996-12       Impact factor: 3.686

4.  Crystallization of blood coagulation factor XIII by an automated procedure.

Authors:  R Hilgenfeld; A Liesum; R Storm; H J Metzner; H E Karges
Journal:  FEBS Lett       Date:  1990-06-04       Impact factor: 4.124

5.  Characterization of the gene for the a subunit of human factor XIII (plasma transglutaminase), a blood coagulation factor.

Authors:  A Ichinose; E W Davie
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

6.  Transglutaminase factor XIII uses proteinase-like catalytic triad to crosslink macromolecules.

Authors:  L C Pedersen; V C Yee; P D Bishop; I Le Trong; D C Teller; R E Stenkamp
Journal:  Protein Sci       Date:  1994-07       Impact factor: 6.725

7.  Three-dimensional structure of a transglutaminase: human blood coagulation factor XIII.

Authors:  V C Yee; L C Pedersen; I Le Trong; P D Bishop; R E Stenkamp; D C Teller
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

8.  Structural evidence that the activation peptide is not released upon thrombin cleavage of factor XIII.

Authors:  V C Yee; L C Pedersen; P D Bishop; R E Stenkamp; D C Teller
Journal:  Thromb Res       Date:  1995-06-01       Impact factor: 3.944

9.  Evolution of transglutaminase genes: identification of a transglutaminase gene cluster on human chromosome 15q15. Structure of the gene encoding transglutaminase X and a novel gene family member, transglutaminase Z.

Authors:  P Grenard; M K Bates; D Aeschlimann
Journal:  J Biol Chem       Date:  2001-06-04       Impact factor: 5.157

10.  Factor XIIIA Calgary: a candidate missense mutation (Leu667Pro) in the beta barrel 2 domain of the factor XIIIA subunit.

Authors:  S Aslam; M C Poon; V C Yee; D J Bowen; G R Standen
Journal:  Br J Haematol       Date:  1995-10       Impact factor: 6.998

View more
  8 in total

1.  Bleeding symptoms in heterozygous factor XIII [corrected] deficiency.

Authors:  Pier Mannuccio Mannucci
Journal:  Haematologica       Date:  2010-09       Impact factor: 9.941

2.  Impaired dimer assembly and decreased stability of naturally recurring R260C mutant A subunit for coagulation factor XIII.

Authors:  Shoko Maeda; Wei Guang Zhang; Masayoshi Souri; Vivien C Yee; Akitada Ichinose
Journal:  J Biochem       Date:  2012-08-25       Impact factor: 3.387

3.  Hemorrhagic-acquired factor XIII deficiency associated with tocilizumab for treatment of rheumatoid arthritis.

Authors:  Masatake Matsuoka; Tokifumi Majima; Tomohiro Onodera; Masahiro Ieko; Masayoshi Souri; Akitada Ichinose; Takashi Kurita; Yasuhiko Kasahara; Masahiro Inoue; Daisuke Takahashi
Journal:  Int J Hematol       Date:  2012-10-16       Impact factor: 2.490

4.  Effects of Factor XIII Deficiency on Thromboelastography. Thromboelastography with Calcium and Streptokinase Addition is more Sensitive than Solubility Tests.

Authors:  M Martinuzzo; L Barrera; D Altuna; F Tisi Baña; J Bieti; Q Amigo; M D'Adamo; M S López; J Oyhamburu; J C Otaso
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-08-16       Impact factor: 2.576

5.  The Plasma Factor XIII Heterotetrameric Complex Structure: Unexpected Unequal Pairing within a Symmetric Complex.

Authors:  Sneha Singh; Alexis Nazabal; Senthilvelrajan Kaniyappan; Jean-Luc Pellequer; Alisa S Wolberg; Diana Imhof; Johannes Oldenburg; Arijit Biswas
Journal:  Biomolecules       Date:  2019-11-21

6.  Mild Acquired Factor XIII Deficiency and Clinical Relevance at the ICU-A Retrospective Analysis.

Authors:  Felix Carl Fabian Schmitt; Maik von der Forst; Wolfgang Miesbach; Sebastian Casu; Markus Alexander Weigand; Sonja Alesci
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

7.  Structural and functional influences of coagulation factor XIII subunit B heterozygous missense mutants.

Authors:  Anne Thomas; Arijit Biswas; Vytautas Ivaskevicius; Johannes Oldenburg
Journal:  Mol Genet Genomic Med       Date:  2015-04-10       Impact factor: 2.183

8.  Revisiting the mechanism of coagulation factor XIII activation and regulation from a structure/functional perspective.

Authors:  Sneha Gupta; Arijit Biswas; Mohammad Suhail Akhter; Christoph Krettler; Christoph Reinhart; Johannes Dodt; Andreas Reuter; Helen Philippou; Vytautas Ivaskevicius; Johannes Oldenburg
Journal:  Sci Rep       Date:  2016-07-25       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.